邁瑞醫療年內接受1882家機構聯合調研 成A股之最 截至三季度股東户數破7.8萬
格隆匯12月22日丨2021年進入尾聲,根據wind統計,截至12月21日晚,2021年以來A股上市公司合計接待14143次機構投資者調研,其中邁瑞醫療接待機構家數最多。2021年以來,邁瑞醫療接待了包括184家基金公司、130家券商、49家保險公司及保險資管公司等在內共計1882家機構的聯合調研。機構密集調研的背後,反映出投資人對其的青睞。根據2021年三季報顯示,邁瑞醫療是機構重倉熱門股之一,截至2021年9月30日,邁瑞醫療股東總數合計78,460户,其中,劉彥春管理的景順長城新興成長、葛蘭管理的中歐醫療健康、唐頤恆管理的富國天益等均重倉持有邁瑞醫療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.